Sorbent Therapeutics, Inc. Appoints Jason Levin Chief Business Officer
12/5/2012 9:28:27 AM
SUNNYVALE, Calif., Dec. 5, 2012 -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Jason Levin has joined the company as Chief Business Officer.
Mr. Levin brings more than 18 years of industry experience to Sorbent. In this newly created role, he will oversee Sorbent's business development efforts and contribute to corporate strategy. Mr. Levin will report directly to Detlef Albrecht, M.D., Sorbent's President and CEO.
"Jason brings significant business development and corporate strategy expertise to our leadership team, and we have already benefitted from his business acumen in his role as an advisor to Sorbent for the past several months," said Dr. Albrecht. "Sorbent's lead product for heart failure, CLP1001, has achieved promising clinical results and our polymer technology platform allows us to create first-in-class therapeutics addressing significant unmet needs in heart failure, chronic kidney disease and hypertension. Jason's contributions to building alliances and forming partnerships will accelerate the development and commercialization of our pipeline programs."
"With positive Phase 2a data for CLP1001, a solid management team and compelling partnering opportunities, this is an exciting time to join Sorbent. CLP1001 has demonstrated measurable clinical improvements in the quality of life for heart failure patients by reducing fluid overload," said Jason Levin. "Sorbent is well positioned for a variety of strategic collaborations as we commence our planned Phase 2b study for CLP1001, and evaluate opportunities to leverage the company's technology platform to generate non-absorbed polymer-based therapeutics that restore fluid and ion balances."
Mr. Levin has been responsible for the completion of significant strategic transactions across several companies generating more than $500 million in value. Before joining Sorbent, Mr. Levin was responsible for in-licensing, out-licensing and partnering as Chief Business Officer at BrainCells Inc. a drug discovery and development company in San Diego, CA. Prior, he was Vice President Corporate Development at Jazz Pharmaceuticals, a specialty pharmaceutical company, where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances. Before joining Jazz Pharmaceuticals, Mr. Levin was director of business development at ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson, where he was responsible for both in- and out-licensing of the company's drug delivery technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, and a Bachelor's Degree from the University of California at San Diego. He has been a member of the Licensing Executive Society since 2000.
Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body. The company is focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, end-stage renal disease, chronic kidney disease and hypertension. Sorbent is headquartered in Sunnyvale, California. For more information, visit www.sorbent.com.
SOURCE Sorbent Therapeutics, Inc.